drugset / Trial / NCT00116181

Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis

NCT00116181

Phase 3 Completed 30 enrolled Rockefeller University Amgen · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigator's laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is to study the action and the effects of Etanercept, on psoriasis. This medication has been studied extensively and has been found to be effective and safe in the treatment of psoriasis. The eligible patient will have 10% of his/her body surface area involved with psoriasis vulgaris. This trial is a phase III study to help understand the action of the drug etanercept, trade name Enbrel, for the adult patient with moderate to severe plaque psoriasis and who is a candidate for internal medications.

Timeline

Start
2004-10
Primary completion
2007-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications